Endoscopic Screening for Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma (ESCC) remains a major global health challenge, particularly in high‐incidence regions of Asia and parts of Africa. Late presentation and rapid progression contribute to a poor prognosis, making early detection strategies crucial. Endoscopic screening serves as a cornerstone of secondary prevention, enabling direct visualisation of the oesophageal mucosa, targeted biopsy of suspicious lesions and immediate intervention for precancerous changes. Conventional white‐light endoscopy supplemented by vital staining, chromoendoscopy and advanced imaging modalities such as narrow‐band imaging and confocal laser endomicroscopy improves lesion detection. In high‐risk populations, systematic screening programmes have demonstrated substantial reductions in mortality by identifying dysplasia and early‐stage carcinoma amenable to endoscopic resection or minimally invasive surgery. Nonetheless, challenges persist in terms of resource allocation, procedural risk, patient adherence and the need for standardised quality metrics. Emerging strategies focus on integrating risk‐prediction models, artificial intelligence‐assisted lesion recognition and precision approaches to tailor screening intervals and methodologies to individual risk profiles. The global significance of endoscopic screening lies in its potential to shift the diagnostic stage distribution, reduce treatment morbidity and improve long‐term survival outcomes for ESCC.

Research from Nature Portfolio

A large population‐based case–control study conducted in a high‐incidence region of northern China demonstrated that individuals who underwent organised endoscopic screening experienced a 47 % reduction in ESCC mortality compared with those never screened. Analysis of screening records and matched controls revealed that the protective effect was most pronounced when screening had occurred within three to four years of diagnosis, underscoring the importance of regular surveillance. These findings provide compelling evidence that systematic, population‐based endoscopic programmes can substantially decrease the fatality of ESCC in rural areas.

Endoscopic Screening for Esophageal Squamous Cell Carcinoma publication trend

The graph below shows the total number of articles in endoscopic screening for esophageal squamous cell carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Endoscopic screening: A procedure using a flexible endoscope to visualise the oesophageal lining, often combined with staining or enhanced imaging, to detect precancerous lesions or early carcinoma.

Squamous dysplasia: An abnormal proliferation of squamous epithelial cells in the oesophagus, graded as low or high grade, representing precancerous changes.

Lugol’s iodine staining: A chromoendoscopy technique in which iodine solution selectively stains normal glycogen‐rich epithelium, rendering dysplastic or neoplastic areas unstained and more readily identifiable.

High‐grade intraepithelial neoplasia (HGIN): A classification of severe epithelial dysplasia characterised by pronounced cellular atypia and architectural disorder, indicating a high risk of progression to invasive carcinoma.

Risk‐prediction model: A statistical tool combining demographic, lifestyle and clinical variables to estimate an individual’s absolute risk of developing ESCC over a defined period, informing personalised screening strategies.

References

1. Effectiveness evaluation of organized screening for esophageal cancer: a case-control study in Linzhou city, China. Scientific Reports (2016).
2. Initial results from a multi-center population-based cluster randomized trial of esophageal and gastric cancer screening in China. BMC Gastroenterology (2020).
3. Precision screening for esophageal squamous cell carcinoma in China. Chinese Journal of Cancer Research (2020).
4. Estimating Individualized Absolute Risk for Esophageal Squamous Cell Carcinoma: A Population-Based Study in High-Risk Areas of China. Frontiers in Oncology (2021).